| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() DG DISPATCH: APA: Treating Premenstrual Dysphoric Disorder By Lara Pullen Special to DG News
CHICAGO, IL -- May 23, 2000 -- Results from several clinical trials indicate that the selective serotonin reuptake inhibitors (SSRIs) have excellent efficacy and minimal side effects in the treatment of premenstrual dysphoric disorder (PMDD). Dr. Meir Steiner of McMaster University, Ontario, Canada reviewed several randomized, placebo-controlled trials studying the effects of SSRIs on the treatment of PMDD at the 2000 Annual Meeting of the American Psychiatric Association, Several SSRI's (fluoxetine, sertraline, paroxetine, clomipramine, fluvoxamine, and citalopram) have been tested for efficacy in the treatment of PMDD and it is difficult to distinguish between them in terms of efficacy. Clomipramine at 25-75 mg was found to be significantly more effective than placebo in reducing irritability as well as other symptoms associated with PMDD (n = 20). In a randomized, controlled trial (n = 65), paroxetine treatment resulted significant reduction in irritability, depression, anxiety, appetite, bloating, and breast tenderness. Another randomized, controlled trial demonstrated that sertraline treatment resulted in significantly decreased depressive symptoms, physical symptoms, and anger/irritability. In the case of clomipramine, paroxetine, and, perhaps, other SSRI's, three cycles of treatment seemed to be required for maximum efficacy. Dr. Steiner concluded by stating that, "Women who are being diagnosed with PMDD are not seeking treatment or help… so the onus is on us to identify them."
|